Junior Chair – Assistant Professor Level in Artificial Intelligence for Drug Discovery

Institute for Translational Medicine and Liver Disease (ITM), Inserm U1110; France; Sur place; EUR 60 000 - 80 000; Plein temps

Avantages offerts par ce poste

Access to high-performance computing clusters

Diverse international setting

Competitive salary dependent on career stage

Résumé du poste

The Institute for Translational Medicine and Liver Disease (ITM), Inserm U1110 in Strasbourg, France, is seeking a Principal Investigator at the Assistant Professor level to develop an AI-driven translational research program in fibrosis and cancer. The ideal candidate will have a strong background in bioinformatics and cancer biology, eager to lead independent research initiatives.

This position offers a competitive salary, access to cutting-edge technologies, and a diverse international research environment fostering collaboration.

Qualifications

• Mid-career (max. 10 years after PhD or MD-PhD) experience required.
• Strong track record in advancing translational medical research.
• Motivation to collaborate with existing teams.

Responsabilités

• Develop a research program on fibrosis and cancer using AI.
• Lead an independent AI-driven research initiative.
• Collaborate with wet-lab and bioinformatics teams.

Connaissances

AI-based analytical methods

Bioinformatics

Cancer biology

Communication in English

Formation

PhD or MD-PhD

Description du poste

The Institute for Translational Medicine and Liver Disease (ITM) Inserm U1110, University of Strasbourg France, directed by Prof. Thomas F. Baumert, is seeking an outstanding Principal Investigator at Assistant Professor level (tenure track) to develop a research program advancing AI-driven translational research in fibrosis and cancer within the framework of a junior chair position. The successful candidate will establish an innovative research program leveraging Artificial Intelligence (AI) and computational approaches to accelerate mechanistic understanding, target identification, and therapeutic development, as part of the ENACT program (https://cluster-ia-enact.ai/). This position will bridge the gap between fundamental research, teaching, and innovation by combining multiple disciplines and partners.

What we are looking for:

• A mid‑career (max. 10 years after PhD or MD‑PhD), bioinformatician, cancer biologist, pharmacist or medical doctor with solid knowledge and track record in applying AI-based analytical methods
• Ability to lead an independent AI-driven research program focused on advancing translational medical research and therapeutic innovation in fibrosis, cancer, and related diseases
• Motivation to collaborate with existing wet‑lab and bioinformatics teams, contributing to the institutes mission
• Strong communicator with command of English, both spoken and written

The successful candidate will benefit from:

• A starting package including PhD student and/or postdoc, computing equipment and running costs Inserm/University of Strasbourg tenure track program
• Access to high-performance computing clusters and advanced data infrastructure provided by both Inserm and the University of Strasbourg
• Access to cutting‑edge technologies including next generation single‑cell RNASeq, spatial transcriptomics platform and patient‑derived models
• A diverse and inclusive international setting where English is a working language, fostering global scientific collaboration
• Competitive salary dependent on career stage and experience, determined by the applicable French civil service/statutory pay scales and benefit package

The institute’s program is highly translational developing transformative solutions for oncology with a focus on fibrosis‑induced liver cancer and is based on key scientific discoveries described in: Aizarani et al. Nature 2019, Hamdane et al. Gastroenterology 2019, Jühling et al. Gut 2021, Crouchet et al. Nat. Commun. 2021, Roehlen et al. Science Translational Med. 2022, Roehlen et al. J. Hepatol. 2023, Del Zompo et al. J. Hepatol. 2025, Crouchet et al. JCI 2025, Nehme et al. Science Translational Med. 2026.